- Home
- ACHC vs ROIV Comparison
ACHC vs ROIV Comparison
Compare ACHC & ROIV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ACHC
- ROIV
- Stock Information
- Founded
- ACHC 2005
- ROIV 2014
- Country
- ACHC United States
- ROIV United Kingdom
- Employees
- ACHC N/A
- ROIV N/A
- Industry
- ACHC Medical Specialities
- ROIV Biotechnology: Pharmaceutical Preparations
- Sector
- ACHC Health Care
- ROIV Health Care
- Exchange
- ACHC Nasdaq
- ROIV Nasdaq
- Market Cap
- ACHC 2.1B
- ROIV 8.4B
- IPO Year
- ACHC N/A
- ROIV N/A
- Fundamental
- Price
- ACHC $25.72
- ROIV $10.67
- Analyst Decision
- ACHC Strong Buy
- ROIV Buy
- Analyst Count
- ACHC 10
- ROIV 4
- Target Price
- ACHC $52.25
- ROIV $17.50
- AVG Volume (30 Days)
- ACHC 3.6M
- ROIV 5.9M
- Earning Date
- ACHC 05-12-2025
- ROIV 05-29-2025
- Dividend Yield
- ACHC N/A
- ROIV N/A
- EPS Growth
- ACHC N/A
- ROIV N/A
- EPS
- ACHC 2.04
- ROIV N/A
- Revenue
- ACHC $3,156,417,000.00
- ROIV $122,585,000.00
- Revenue This Year
- ACHC $7.90
- ROIV N/A
- Revenue Next Year
- ACHC $8.58
- ROIV N/A
- P/E Ratio
- ACHC $12.60
- ROIV N/A
- Revenue Growth
- ACHC 5.48
- ROIV 140.04
- 52 Week Low
- ACHC $20.36
- ROIV $8.73
- 52 Week High
- ACHC $82.41
- ROIV $13.06
- Technical
- Relative Strength Index (RSI)
- ACHC 53.03
- ROIV 47.82
- Support Level
- ACHC $23.83
- ROIV $10.58
- Resistance Level
- ACHC $28.48
- ROIV $11.77
- Average True Range (ATR)
- ACHC 1.29
- ROIV 0.34
- MACD
- ACHC 0.71
- ROIV -0.07
- Stochastic Oscillator
- ACHC 61.56
- ROIV 7.56
About ACHC Acadia Healthcare Company Inc.
Acadia Healthcare Co Inc acquires and develops behavioral healthcare facilities. Acute inpatient psychiatric facilities and specialty treatment facilities contribute the vast majority of Acadia's revenue in the United States. The company's revenue is derived from services rendered to patients for inpatient psychiatric and substance abuse care, outpatient psychiatric care, and adolescent residential treatment.
About ROIV Roivant Sciences Ltd.
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.